Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058965 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
A Early Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT03058965 is a Early Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 12 participants.
The verdict
NCT03058965, a Early Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall goal of this imaging trial is to evaluate \[18F\]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
Interventions
- DRUG [18F]Florbetapir
- DRUG DaTscan
- DRUG [18F]MNI-958
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2018-05-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03058965
The ClinicalTrials.gov registry entry for NCT03058965 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [18F]Florbetapir is the first listed.
NCT03058965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03058965 about?
NCT03058965 is a clinical study titled "Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain". The overall goal of this imaging trial is to evaluate \[18F\]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
What is the current status of trial NCT03058965?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2016-11-29. Estimated completion is 2018-05-11.
What interventions are being tested in trial NCT03058965?
The interventions under investigation include: [18F]Florbetapir (DRUG), DaTscan (DRUG), [18F]MNI-958 (DRUG).
Who is sponsoring clinical trial NCT03058965?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.